awmsg logo



C1-esterase inhibitor (Berinert®)


Reference No. 1425

Publication date:
31/07/2013


Last review date:
30/09/2016

Appraisal information

C1-esterase inhibitor (Berinert®) 500 units powder and solvent for solution for injection/infusion


Company: CSL Behring UK Ltd
BNF category: Respiratory system
NMG meeting date: 15/05/2013
AWMSG meeting date: 12/06/2013
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1613
Ministerial ratification: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

C1-esterase inhibitor (Berinert®) is recommended as an option for use within NHS Wales for the treatment of acute episodes of hereditary angioedema type I and II. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download